Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with Calcineurin inhibition to promote T-ALL cell death

Valeria Tosello, Valentina Saccomani, Jiyang Yu, Fulvio Bordin, Alberto Amadori, Erich Piovan

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Calcineurin (Cn) is a calcium activated protein phosphatase involved in many aspects of normal T cell physiology, however the role of Cn and/or its downstream targets in leukemogenesis are still ill-defined. In order to identify putative downstream targets/effectors involved in the pro-oncogenic activity of Cn in T-cell acute lymphoblastic leukemia (T-ALL) we used tandem affinity chromatography, followed by mass spectrometry to purify novel Cn-interacting partners. We found the Cn-interacting proteins to be part of numerous cellular signaling pathways including eIF2 signaling and mTOR signaling. Coherently, modulation of Cn activity in T-ALL cells determined alterations in the phosphorylation status of key molecules implicated in protein translation such as eIF-2α and ribosomal protein S6. Joint targeting of PI3K-mTOR, eIF-2α and 14-3-3 signaling pathways with Cn unveiled novel synergistic pro-apoptotic drug combinations. Further analysis disclosed that the synergistic interaction between PI3K-mTOR and Cn inhibitors was prevalently due to AKT inhibition. Finally, we showed that the synergistic pro-apoptotic response determined by jointly targeting AKT and Cn pathways was linked to down-modulation of key anti-apoptotic proteins including Mcl-1, Claspin and XIAP. In conclusion, we identify AKT inhibition as a novel promising drug combination to potentiate the proapoptotic effects of Cn inhibitors.

Original languageEnglish
Pages (from-to)45715-45729
Number of pages15
JournalOncotarget
Volume7
Issue number29
DOIs
Publication statusPublished - 2016

Fingerprint

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Calcineurin
Cell Death
Drug Combinations
Phosphatidylinositol 3-Kinases
Ribosomal Protein S6
Cell Physiological Phenomena
Apoptosis Regulatory Proteins
Phosphoprotein Phosphatases
Prodrugs
Protein Biosynthesis
Affinity Chromatography
Mass Spectrometry
Joints
Phosphorylation
Calcium
T-Lymphocytes

Keywords

  • Apoptosis
  • Calcineurin
  • MTOR signaling
  • Protein complex
  • T-cell acute lymphoblastic leukemia

ASJC Scopus subject areas

  • Oncology

Cite this

@article{64b7b35cb125463da1d7bc660967fa2f,
title = "Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with Calcineurin inhibition to promote T-ALL cell death",
abstract = "Calcineurin (Cn) is a calcium activated protein phosphatase involved in many aspects of normal T cell physiology, however the role of Cn and/or its downstream targets in leukemogenesis are still ill-defined. In order to identify putative downstream targets/effectors involved in the pro-oncogenic activity of Cn in T-cell acute lymphoblastic leukemia (T-ALL) we used tandem affinity chromatography, followed by mass spectrometry to purify novel Cn-interacting partners. We found the Cn-interacting proteins to be part of numerous cellular signaling pathways including eIF2 signaling and mTOR signaling. Coherently, modulation of Cn activity in T-ALL cells determined alterations in the phosphorylation status of key molecules implicated in protein translation such as eIF-2α and ribosomal protein S6. Joint targeting of PI3K-mTOR, eIF-2α and 14-3-3 signaling pathways with Cn unveiled novel synergistic pro-apoptotic drug combinations. Further analysis disclosed that the synergistic interaction between PI3K-mTOR and Cn inhibitors was prevalently due to AKT inhibition. Finally, we showed that the synergistic pro-apoptotic response determined by jointly targeting AKT and Cn pathways was linked to down-modulation of key anti-apoptotic proteins including Mcl-1, Claspin and XIAP. In conclusion, we identify AKT inhibition as a novel promising drug combination to potentiate the proapoptotic effects of Cn inhibitors.",
keywords = "Apoptosis, Calcineurin, MTOR signaling, Protein complex, T-cell acute lymphoblastic leukemia",
author = "Valeria Tosello and Valentina Saccomani and Jiyang Yu and Fulvio Bordin and Alberto Amadori and Erich Piovan",
year = "2016",
doi = "10.18632/oncotarget.9933",
language = "English",
volume = "7",
pages = "45715--45729",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "29",

}

TY - JOUR

T1 - Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with Calcineurin inhibition to promote T-ALL cell death

AU - Tosello, Valeria

AU - Saccomani, Valentina

AU - Yu, Jiyang

AU - Bordin, Fulvio

AU - Amadori, Alberto

AU - Piovan, Erich

PY - 2016

Y1 - 2016

N2 - Calcineurin (Cn) is a calcium activated protein phosphatase involved in many aspects of normal T cell physiology, however the role of Cn and/or its downstream targets in leukemogenesis are still ill-defined. In order to identify putative downstream targets/effectors involved in the pro-oncogenic activity of Cn in T-cell acute lymphoblastic leukemia (T-ALL) we used tandem affinity chromatography, followed by mass spectrometry to purify novel Cn-interacting partners. We found the Cn-interacting proteins to be part of numerous cellular signaling pathways including eIF2 signaling and mTOR signaling. Coherently, modulation of Cn activity in T-ALL cells determined alterations in the phosphorylation status of key molecules implicated in protein translation such as eIF-2α and ribosomal protein S6. Joint targeting of PI3K-mTOR, eIF-2α and 14-3-3 signaling pathways with Cn unveiled novel synergistic pro-apoptotic drug combinations. Further analysis disclosed that the synergistic interaction between PI3K-mTOR and Cn inhibitors was prevalently due to AKT inhibition. Finally, we showed that the synergistic pro-apoptotic response determined by jointly targeting AKT and Cn pathways was linked to down-modulation of key anti-apoptotic proteins including Mcl-1, Claspin and XIAP. In conclusion, we identify AKT inhibition as a novel promising drug combination to potentiate the proapoptotic effects of Cn inhibitors.

AB - Calcineurin (Cn) is a calcium activated protein phosphatase involved in many aspects of normal T cell physiology, however the role of Cn and/or its downstream targets in leukemogenesis are still ill-defined. In order to identify putative downstream targets/effectors involved in the pro-oncogenic activity of Cn in T-cell acute lymphoblastic leukemia (T-ALL) we used tandem affinity chromatography, followed by mass spectrometry to purify novel Cn-interacting partners. We found the Cn-interacting proteins to be part of numerous cellular signaling pathways including eIF2 signaling and mTOR signaling. Coherently, modulation of Cn activity in T-ALL cells determined alterations in the phosphorylation status of key molecules implicated in protein translation such as eIF-2α and ribosomal protein S6. Joint targeting of PI3K-mTOR, eIF-2α and 14-3-3 signaling pathways with Cn unveiled novel synergistic pro-apoptotic drug combinations. Further analysis disclosed that the synergistic interaction between PI3K-mTOR and Cn inhibitors was prevalently due to AKT inhibition. Finally, we showed that the synergistic pro-apoptotic response determined by jointly targeting AKT and Cn pathways was linked to down-modulation of key anti-apoptotic proteins including Mcl-1, Claspin and XIAP. In conclusion, we identify AKT inhibition as a novel promising drug combination to potentiate the proapoptotic effects of Cn inhibitors.

KW - Apoptosis

KW - Calcineurin

KW - MTOR signaling

KW - Protein complex

KW - T-cell acute lymphoblastic leukemia

UR - http://www.scopus.com/inward/record.url?scp=84979896367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979896367&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9933

DO - 10.18632/oncotarget.9933

M3 - Article

AN - SCOPUS:84979896367

VL - 7

SP - 45715

EP - 45729

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 29

ER -